Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 9Head & Neck 3Genitourinary 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Biopsy, Needle × Thoracic × Clear all
NCT01259089 2019-09-11

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Northwestern University

Phase 1/2 Completed
38 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT00673569 2010-08-09

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡